Evidence map›Paper›PMID 35683393›Full record

ArticleJournal of clinical medicine2022

Reperfusion Therapies for Acute Ischemic Stroke in COVID-19 Patients: A Nationwide Multi-Center Study.

Justina Jurkevičienė, Mantas Vaišvilas, Rytis Masiliūnas, Vaidas Matijošaitis, Antanas Vaitkus, Dovilė Geštautaitė, Saulius Taroza, Paulius Puzinas, Erika Galvanauskaitė, Dalius Jatužis and 1 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Justina JurkevičienėStroke Centre, Republican Vilnius University Hospital, 04130 Vilnius, Lithuania.ORCID 0000-0002-0746-1745
Mantas VaišvilasStroke Centre, Republican Vilnius University Hospital, 04130 Vilnius, Lithuania.
Rytis MasiliūnasCenter of Neurology, Vilnius University, 08661 Vilnius, Lithuania.ORCID 0000-0002-8033-9682
Vaidas MatijošaitisDepartment of Neurology, Lithuanian University of Health Sciences, 50009 Kaunas, Lithuania.
Antanas VaitkusDepartment of Neurology, Lithuanian University of Health Sciences, 50009 Kaunas, Lithuania.
Dovilė GeštautaitėDepartment of Neurology, Lithuanian University of Health Sciences, 50009 Kaunas, Lithuania.
Saulius TarozaLaboratory of Behavioral Medicine (Palanga), Neuroscience Institute, Lithuanian University of Health Sciences, 00135 Palanga, Lithuania.ORCID 0000-0002-9067-7810
Paulius PuzinasDepartment of Neurology, Republican Panevėžys Hospital, 35144 Panevėžys, Lithuania.
Erika GalvanauskaitėDepartment of Neurology, Republican Šiauliai Hospital, 76231 Šiauliai, Lithuania.
Dalius JatužisCenter of Neurology, Vilnius University, 08661 Vilnius, Lithuania.ORCID 0000-0001-6159-4795
Aleksandras VilionskisClinic of Neurology and Neurosurgery, Vilnius University, 03101 Vilnius, Lithuania.ORCID 0000-0002-8055-3558

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Acute ischemic stroke (AIS) is a possible complication of the coronavirus disease 2019 (COVID-19). Safety and efficacy data on reperfusion therapies (RT)-intravenous thrombolysis and endovascular treatment (EVT)-in stroke patients with COVID-19 is lacking. (2) Methods: We performed a retrospective nationwide multi-center pair-matched analysis of COVID-19 patients with AIS who underwent RT. We included adult COVID-19 patients with AIS who were treated with RT between 16 March 2020 and 30 June 2021. All subjects were paired with non-infected controls, matched for age, sex, stroke arterial vascular territory, and RT modality. The primary outcome measure was a favorable functional outcome defined by the modified Rankin scale (mRS 0-2). (3) Results: Thirty-one subjects and thirty-one matched controls were included. The median baseline National Institutes of Health Stroke Scale (NIHSS) score was higher in the COVID-19 group (16 vs. 12,

Indexed as

COVID-19ischemic strokeLithuaniaoutcomesreperfusion therapiessafetythrombectomythrombolysis

Identifiers

PMID35683393
PMCPMC9181080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.